Incyte

Incyte scraps anemia program after drug fails to improve symptoms in rare blood cancer
Fierce Biotech
Sun, 12/15/24 - 10:46 pm
Incyte
myelofibrosis
anemia
zilurgisertib
Incyte sinks on setback for drugs acquired in $750M buyout
BioPharma Dive
Tue, 11/19/24 - 07:10 pm
Incyte
Escient Pharma
M&A
Incyte blocks US launch of Sun Pharma's alopecia drug
Pharmaphorum
Mon, 11/4/24 - 11:10 am
Incyte
Sun Pharma
Leqselvi
alopecia areata
With Jakafi's patent cliff looming, Incyte looks to 2025 launches to bulk up revenue by decade's end
Fierce Pharma
Wed, 10/30/24 - 11:42 am
Incyte
Jakafi
patent cliff
Niktimvo
graft vs host disease
Monjuvi
follicular lymphoma
Zynyz
squamous cell anal carcinoma
ESMO: Even after unique trial win, Incyte CEO views PD-1 drug Zynyz as pipeline aide
Fierce Pharma
Sun, 09/15/24 - 06:27 pm
Incyte
Zynyz
ESMO
Incyte and Syndax's immunotherapy for transplant complications receives FDA approval
Biopharma Reporter
Tue, 08/20/24 - 11:49 am
Incyte
Syndax
immunotherapy
Niktimvo
graft vs host disease
Armed with Phase III win, Incyte eyes label expansion for Monjuvi
Clinical Trials Arena
Fri, 08/16/24 - 11:19 am
Incyte
clinical trials
Monjuvi
relapsed or refractory follicular lymphoma
FDA approves Incyte's treatment for chronic graft-versus-host disease
Reuters
Wed, 08/14/24 - 10:37 pm
Incyte
FDA
graft vs host disease
Niktimvo
Incyte drops pair of PD-L1 drugs as part of 2nd pipeline clear-out this year
Fierce Biotech
Tue, 07/30/24 - 11:44 am
Incyte
anti-PD-L1
Incyte plots Delaware expansion as it looks to re-wed commercial, medical teams in its home state
Fierce Pharma
Tue, 05/21/24 - 06:56 pm
Incyte
Delaware
Opzelura
Incyte Inks $750M Deal to Buy Escient and Skin Disease Drug Candidates
BioSpace
Tue, 04/23/24 - 09:46 pm
Incyte
M&A
Escient Pharma
atopic dermatitis
Incyte, itching for a piece of Dupixent's market, hits goals in midphase skin disease trial
Fierce Biotech
Mon, 03/11/24 - 11:52 am
Incyte
clinical trials
prurigo nodularis
povorcitinib
Dupixent
Sanofi
Regeneron
Incyte vets, with phase 1 within reach, raise $102M for new biotech to create better PARP, PI3K drugs
Fierce Biotech
Wed, 01/24/24 - 10:35 am
Synnovation Therapeutics
Incyte
AstraZeneca
GSK
Novartis
Pfizer
funding
cancer
PARP inhibitors
Incyte reports positive data from Phase III vitiligo trial
Clinical Trials Arena
Thu, 10/12/23 - 05:27 pm
Incyte
Opzelura
vitiligo
clinical trials
Replimune and Incyte to study cancer combo therapy in CSCC patients
Clinical Trials Arena
Tue, 08/1/23 - 10:06 am
Replimmune
Incyte
clinical trials
RP1
CSCC
cutaneous squamous cell carcinoma
Incyte’s trial of ruxolitinib cream meets primary endpoint
Clinical Trials Arena
Wed, 07/12/23 - 09:37 am
Incyte
ruxolitinib
clinical trials
pediatric
atopic dermatitis
Blood cancer trial finds ruxolitinib better than current treatments
Clinical Trials Arena
Fri, 05/5/23 - 10:13 am
clinical trials
polycythemia vera
Jakafi
Incyte
Incyte whittles down pipeline, scrapping 6 R&D programs
Fierce Biotech
Tue, 05/2/23 - 11:25 pm
Incyte
R7D
anemia
cancer
Biotech heads towards big catalysts
EP Vantage
Tue, 03/28/23 - 10:24 am
biotech
clinical trials
Alnylam Pharmaceuticals
Arcus Biosciences
Argenx
Arrowhead Pharmaceuticals
Axsome Therapeutics
Bavarian Nordic
FibroGen
Gilead Sciences
Incyte
Morphic Therapeutic
PTC Therapeutics
Syndax Pharmaceuticals
Travere Therapeutics
Vaxcyte
Incyte hit by CRL on extended-release JAK tablets, muddying plans for Jakafi franchise expansion
Endpoints
Fri, 03/24/23 - 10:05 am
Incyte
FDA
ruxolitinib
CRL

Pages